Searched for
INSULIN MARKET OPPORTUNITY
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Biocon Biologics looks to trim $300 million debt in 1 yearBiocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in d...
- Eris enters JV with MJ Pharma to commercialise insulins in domestic marketThe business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.
- Biocon eyes $30b US insulin market via its biosimilarsWith the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...
- Biocon Biologics to partner with International Diabetes FederationGlobal Head of Market Access & Policy, Biocon Biologics, Alexander Zach, said:"Given our extensive experience in providing affordable insul...
- Biocon, Mylan win US court ruling in favour of insulin GlargineUS District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...
- Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...
- Latest launches to help Biocon reach billion-dollar biosimilar sales by 2022: Kiran Mazumdar ShawHerceptin is a biosimilar trastuzumab is going to be a major launch for both Biocon & Mylan.
- Biocon links with Mexico's PiSA to tap US insulin marketBiocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at ...
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...
- Biocon seals Rs 1,550 cr pact with PfizerThe agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
- Aventis Pharma launches disposable insulin penPharmaceutical company Aventis Pharma Limited toady launched a new prefilled disposable insulin pen diabetic patients and aims at increasin...
Load More
